Media headlines about Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Isotechnika Pharma earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.7390379321858 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

AUPH stock opened at $5.35 on Friday. The stock has a market cap of $452.20, a price-to-earnings ratio of -5.82 and a beta of 2.26. Isotechnika Pharma has a one year low of $4.41 and a one year high of $8.19.

Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.10. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. Isotechnika Pharma had a negative net margin of 16,855.24% and a negative return on equity of 17.54%. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.11) earnings per share. equities research analysts predict that Isotechnika Pharma will post -0.7 EPS for the current year.

AUPH has been the subject of a number of research reports. Seaport Global Securities reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Isotechnika Pharma in a research note on Friday, March 16th. ValuEngine raised shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. BidaskClub raised shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. Zacks Investment Research raised shares of Isotechnika Pharma from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, Royal Bank of Canada assumed coverage on shares of Isotechnika Pharma in a research report on Thursday, February 8th. They set an “outperform” rating and a $9.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Isotechnika Pharma currently has an average rating of “Buy” and an average target price of $10.92.

Isotechnika Pharma Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.

Insider Buying and Selling by Quarter for Isotechnika Pharma (NASDAQ:AUPH)

Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.